天然产物合成生物学体系的优化策略

天然产物是新药研发的重要源泉。天然产物合成生物学通过设计、重构目标化合物的高效生物合成途径,借助宿主改造,利用发酵生产目标化合物,可以有效弥补有机合成化学在复杂天然产物类药物生产方面的不足。虽然合成生物学已经取得了一些进展,但是通过合成生物学技术使目标产物的产量达到工业化生产水平依然是一项非常具有挑战性的任务。综述了天然产物合成生物学体系的优化策略,通过综合运用单个元件、外源代谢途径、底盘系统和发酵条件的优化技术,可以实现生物合成系统的最优化,最大化目标产物的产量,为来源稀缺的复杂天然产物的开发提供持续、稳定、经济的原料供给,推动天然产物类新药的研发。     

植物来源药用天然产物的合成生物学研究进展

大多数药用天然产物在植物中含量低微,提取分离困难;而且这些化合物一般结构复杂,化学合成难度大,还容易造成环境污染。基于合成生物学技术获得药用天然产物具有绿色环保和可持续发展等优点。文中以药用萜类化合物人参皂苷、紫杉醇、青蒿素、丹参酮,生物碱类化合物长春新碱、吗啡以及黄酮类化合物灯盏花素为例,总结了植物来源药用萜类、生物碱类和黄酮类化合物的生物合成途径及合成生物学研究进展,介绍了药用天然产物合成生物学研究的关键技术与方法,并展望了合成生物学技术在药用天然产物研究与开发方面的应用前景。     

天然产物的生物合成专刊序言

天然产物是创新药物、食品、香料和日化产品等的重要来源,和人民的健康生活息息相关。近年来,随着现代生物学技术和天然产物化学技术的发展和融合,天然产物生物合成研究得到了迅猛的发展。一批天然产物的生物合成途径被解析,许多天然产物生物合成相关的途径酶与后修饰酶被挖掘和功能表征。进一步,这些参与天然产物生物合成的途径酶编码基因被组装到不同的底盘细胞中,利用合成生物学技术构建细胞工厂,用于天然产物的生物合成。此外,包括基因组编辑等新技术在内的生物技术也被用于天然产物的生物合成。为了进一步促进天然产物生物合成研究的发展,《生物工程学报》特组织出版"天然产物的生物合成"专刊,重点阐述了在天然产物生物合成途径的解析,工具酶的挖掘和功能表征以及生物合成技术制备天然产物三方面所取得的研究进展,并展望未来的发展趋势,为天然产物生物合成的进一步发展提供借鉴和指导。     

天然药物研究中的合成生物学

天然产物一直是药物分子设计和开发过程中的重要灵感来源之一,源自天然产物的临床用药目前也占据着难以替代的地位.但是大多数天然来源的药物分子结构复杂、分离困难,利用传统的合成化学和天然产物化学方法难以满足日益增长的市场需求.天然产物在其产生物种中一定对应着一个由若干功能各异的基因元件所构成的生物合成基因群,或成簇分布或离散分布.合成生物学则旨在通过对不同基因元件的改造、组合、拼装而得到新的生物途径和体系.本文主要将针对合成生物学在天然药物研究中的应用进行总结和展望,并从基因元件以及合成生物学的角度重新认识和理解天然产物的生物合成.     

合成生物学在天然产物研究中的应用

天然产物作为临床用药的重要组成部分和新药发现的重要来源,已经成为医药领域不可或缺的成员之一。但是传统的天然产物筛选方法在一定程度上制约了新型天然产物的开发,鉴别与改造天然产物的生物合成路径为全新天然产物的发现提供了思路。近年来,生物信息学和合成生物学技术的蓬勃发展为天然产物的探索与改造带来了新的曙光。归纳总结了合成生物学技术相关的基因重组策略和基因簇调控方法,并讨论了其在天然产物研究中的应用及存在的问题。     

天然产物生物合成与抗肿瘤药物合成生物学研究

结构复杂多样的天然产物是现代药物的重要组成部分和新药发现的重要源泉.天然产物的生物合成研究,是从基因和蛋白水平阐明天然产物的合成途径,通过酶催化的化学反应将基因与化合物的结构单元建立一种对应关系,从而理解自然界神奇的化学合成、生物拮抗及生理调控过程.天然产物的合成生物学研究核心是通过在发酵友好、高效的微生物中设计、构建目标化合物的生物合成途径,经系统地调控和优化重组微生物,从而发酵生产来源稀缺的天然产物类药物、前体或新化合物.本文结合相关领域的进展,对本研究组近年来关于抗肿瘤天然产物生物合成及抗癌药物合成生物学的工作进行系统的介绍.     

芳香类天然产物的合成生物学研究进展

植物芳香类天然产物具有重要的药用价值,可制成具有抗菌、抗炎、镇痛、抗氧化、杀虫驱虫、祛痰止咳、安神镇静和抗肿瘤等药效的医药保健用品。然而,由于植物中芳香类天然产物含量较低并且难以提取和纯化,严重限制了其工业化生产及应用。合成生物学和代谢工程技术的发展为天然产物的生产提供了新的思路,可以利用人工微生物细胞工厂来实现多种芳香类天然产物的高效合成。文中介绍了芳香类天然产物的种类、合成途径和关键酶,综述了近年来国内外通过合成生物学技术合成芳香类天然产物的研究进展,探讨了当前研究所面临的挑战及潜在的解决策略,以期对芳香类天然产物生物合成研究工作提供参考。     

国家自然科学基金委员会生命科学部2013年度优秀青年科学基金项目

项目名称 真菌分类学 天然产物生物合成与合成生物学 微生物组研究方法学 植物病毒学 蓝光调控植物开花时间的机制研究 植物结构生物学     

链霉菌底盘细胞的开发现状及其应用

天然产物及其衍生物在现代医疗中扮演着举足轻重的角色,其生物活性多样性以及化学结构的丰富性是新药研发的源泉和动力。利用纯化学方法合成天然产物在技术和成本上有很大的困难,加上许多天然产物的原始产生菌具有培养条件苛刻、产量低下等缺点,而且大量基因簇在原始菌株中是沉默的,这使得利用合成生物学思想来指导天然产物生物合成基因簇的异源表达具有重大意义。作为抗生素、抗肿瘤活性物质、免疫抑制剂等次级代谢产物主要来源的放线菌一直是研究者们关注的焦点,特别是随着基因测序技术的飞速发展,人们发现链霉菌基因组中包含着极为丰富的天然产物生物合成基因簇资源。这意味着开发链霉菌底盘细胞作为异源表达宿主有其得天独厚的优势。本综述从底盘细胞开发的意义入手,重点阐述链霉菌底盘细胞构建的策略及现状,随后通过实例阐述了各种底盘链霉菌的实际应用。     

CRISPR/Cas9在放线菌合成生物学研究中的应用和发展

放线菌是活性天然产物和抗生素药物的重要来源。利用合成生物学高效地开发其中丰富的天然产物资源,将为加速新药开发奠定坚实的基础。CRISPR/Cas9作为一种多功能基因编辑系统,因其便捷高效而被广泛应用于真核生物的遗传操作。但在原核生物尤其是放线菌中的应用仍处于起步阶段,机遇和挑战并存。本综述总结了目前CRISPR/Cas9系统在放线菌基因编辑和调控,以及活性天然产物的产量提升、生物合成机制解析和资源开发等方面的研究进展。同时,也对该系统在应用中面临的包括重组修复效率低,以及靶向切割效率不足等关键挑战进行了分析,并提出了相应的优化解决方法。随着CRISPR/Cas9在放线菌应用中的不断完善和发展,将极大地推动放线菌的合成生物学研究,促进其中天然产物资源的有效挖掘和应用开发。     

Microbial production of small medicinal molecules and biologics: From nature to synthetic pathways

Natural products are promising chemicals due to their structural diversity and bioactivities. Over the decades, a vast variety of gene clusters encoding natural products have been identified and overexpressed in microbes. Recently, the development of metabolic engineering, synthetic biology and bioinformatics strategies have facilitated target discovery and design. Microbial cells have been therefore constantly engineered for product accumulation. This review summarizes approaches of domesticating microbial hosts in producing major classes of natural products, with an emphasis on recent advances.     

天然产物类药物的合成生物学研究

结构复杂多样的天然产物是现代药物的重要组成部分和新药发现的重要源泉。建立在基因工程及代谢工程、合成化学、基因组学、系统生物学等学科基础上的合成生物学研究对于结构复杂的天然产物类药物研究有特殊的意义。核心是通过在发酵友好、高效的微生物中设计、构建目标化合物的生物合成途径,经系统地调控和优化由重组微生物发酵生产来源稀缺的天然产物类药物或前体。该方法是不远的将来解决来源、成本与环境、资源协调问题最好的途径之一,也是解决海洋天然产物或特殊生境微生物药物面临的如何持续供应化合物这一个瓶颈问题的最佳选择。该文将对天然产物类药物合成生物学研究涉及的主要策略和重要进展进行阐述。     

Synthetic biology for natural product drug production and engineering

Natural products continue to provide privileged scaffolds for drug discovery. However, challenges in supply and structure diversification can limit development. Here, we discuss recent (2017–2020) examples of synthetic biology approaches used to address challenges in supply and contribute to structure diversification of selected plant and bacterial natural products. Our examples include plant terpenoids, alkaloids, and lignans and bacterial polyketides, nonribosomal peptides, and ribosomally synthesized and posttranslationally modified peptides.     

Synthetic biology and metabolic engineering of actinomycetes for natural product discovery

Actinomycetes are one of the most valuable sources of natural products with industrial and medicinal importance. After more than half a century of exploitation, it has become increasingly challenging to find novel natural products with useful properties as the same known compounds are often repeatedly re-discovered when using traditional approaches. Modern genome mining approaches have led to the discovery of new biosynthetic gene clusters, thus indicating that actinomycetes still harbor a huge unexploited potential to produce novel natural products. In recent years, innovative synthetic biology and metabolic engineering tools have greatly accelerated the discovery of new natural products and the engineering of actinomycetes. In the first part of this review, we outline the successful application of metabolic engineering to optimize natural product production, focusing on the use of multi-omics data, genome-scale metabolic models, rational approaches to balance precursor pools, and the engineering of regulatory genes and regulatory elements. In the second part, we summarize the recent advances of synthetic biology for actinomycetal metabolic engineering including cluster assembly, cloning and expression, CRISPR/Cas9 technologies, and chassis strain development for natural product overproduction and discovery. Finally, we describe new advances in reprogramming biosynthetic pathways through polyketide synthase and non-ribosomal peptide synthetase engineering. These new developments are expected to revitalize discovery and development of new natural products with medicinal and other industrial applications.     

基于CRISPR/Cas系统的天然产物生物合成基因簇克隆和编辑技术

合成生物学和基因组测序技术的快速发展使挖掘和高效合成天然产物进入了一个全新的时代。由于多数原始菌株生长缓慢、难以培养及遗传改造困难等问题,导致天然产物生物合成基因簇的激活和高效表达受到严重制约。基于此,将原始菌株来源的基因簇转移到操作简便、遗传背景清晰的模式宿主中进行异源表达成为天然产物发现和产量提高的一种有效手段。其中,基因簇的克隆与编辑是实现天然产物异源表达的一个主要限速步骤。CRISPR/Cas技术的应用极大地提高了大型基因簇克隆和编辑的效率,有效促进了微生物来源新药的发现。本文针对基于CRISPR/Cas开发的基因簇克隆和编辑技术进行了系统梳理和全面总结,探讨相关技术在天然产物挖掘和高效合成中的应用及其重要意义。     

Natural products from synthetic biology

DNA sequencing has uncovered microbial secondary metabolic potential that never surfaced in fermentation based screens. Deep and cheap sequencing of a genus such as Streptomyces can rapidly expose hundreds of metabolic genes and operons. Meanwhile, synthetic biologists, in their quest to engineer advanced biofuels, are mastering metabolic engineering. Natural products, a reliable source of new therapeutic leads for many years, have fallen into disfavor with drug discoverers partly because these molecules are rarely available as pure compounds and sourcing is often problematic. The convergence of next generation sequencing and synthetic biology, along with less spectacular progress in analytic technologies such as mass spectroscopy, opens the door to the creation of large, reliable libraries of pure natural products for drug discovery.     

Recent advances in natural products exploitation in Streptomyces via synthetic biology

Natural products of microbial origin have proven to be the wellspring of clinically useful compounds for human therapeutics. Streptomyces species are predominant sources of bioactive compounds, most of which serve as potential drug candidates. While the exploitation of natural products has been severely reduced over the past two decades, the growing crisis of evolution and dissemination of drug resistant pathogens have again attracted great interest in this field. The emerging synthetic biology has been heralded as a new bioengineering platform to discover novel bioactive compounds and expand bioactive natural products diversity and production. Herein, we review recent advances in the natural products exploitation of Streptomyces with the applications of synthetic biology from three major aspects, including recently developed synthetic biology tools, natural products biosynthetic pathway engineering strategies as well as chassis host modifications.     

Rational engineering strategies for achieving high-yield,high-quality and high-stability of natural product production in actinomycetes

Actinomycetes are recognized as excellent producers of microbial natural products, which have a wide range of applications, especially in medicine, agriculture and stockbreeding. The three main indexes of industrialization (titer, purity and stability) must be taken into overall consideration in the manufacturing process of natural products. Over the past decades, synthetic biology techniques have expedited the development of industrially competitive strains with excellent performances. Here, we summarize various rational engineering strategies for upgrading the performance of industrial actinomycetes, which include enhancing the yield of natural products, eliminating the by-products and improving the genetic stability of engineered strains. Furthermore, the current challenges and future perspectives for optimizing the industrial strains more systematically through combinatorial engineering strategies are also discussed.     

Natural products as a screening resource

Natural products have been the most productive source of leads for new drugs, but they are currently out of fashion with the pharmaceutical industry. New approaches to sourcing novel compounds from untapped areas of biodiversity coupled with the technical advances in analytical techniques (such as microcoil NMR and linked LC-MS-NMR) have removed many of the difficulties in using natural products in screening campaigns. As the 'chemical space' occupied by natural products is both more varied and more drug-like than that of combinatorial chemical collections, synthetic and biosynthetic methods are being developed to produce screening libraries of natural product-like compounds. A renaissance of drug discovery inspired by natural products can be predicted.     

Application of natural products derivatization method in the design of targeted anticancer agents from 2000 to 2018

A concept, natural products derivatization method (NPDM), was introduced to assess the influence of natural products on the discovery of targeted anticancer agents. Subsequently, 106 new molecular entities (NMEs) for targeted anticancer agents from 2000 to 2018 were categorized and sorted into four types: ND (Natural Product Derivative), SND (Synthetic Natural Derived), B (Biological Macromolecule), S (Totally synthetic in origin). Furthermore, by setting molecular targeted agents (MTA), cellular targeted agents (CTA), vascular targeted agents (VTA) and immuno targeted agents (ITA) as study subject, ND category and SND category were reviewed from aspects including natural products source, action mechanism and their share in all NMEs in order to comprehensively evaluate the significance of NPDM in the design and development of targeted anticancer agents, and the prospects of this method was also put forward.